Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $8.13 Consensus Target Price from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned a consensus rating of “Hold” from the five brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.30.

ESPR has been the topic of a number of recent analyst reports. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Thursday, December 12th. Finally, The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price target for the company.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ESPR. BOKF NA acquired a new stake in Esperion Therapeutics in the second quarter valued at $26,000. Traphagen Investment Advisors LLC bought a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at about $27,000. Xponance Inc. acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at about $28,000. National Bank of Canada FI raised its position in shares of Esperion Therapeutics by 115.9% during the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in shares of Esperion Therapeutics in the second quarter worth approximately $44,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Stock Performance

Shares of ESPR opened at $2.19 on Wednesday. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94. The firm has a market cap of $431.51 million, a price-to-earnings ratio of -3.42 and a beta of 1.01. The business’s fifty day moving average is $2.42 and its 200-day moving average is $2.22.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.